ReviewPharmaceuticals (Basel, Switzerland)2022
The Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical Trials.
Review in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.BMJ (Clinical research ed.) · 2023Pooled it
- Trial
- Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis.Drug and alcohol dependence · 2024Trial
- X-ray crystal structures of the cannabinoid synthases CBCAS, CBDAS and THCAS.Current research in structural biology · 2026Article
- Bedtime tetrahydrocannabinol ingestion reduces morning orthostatic cardiovascular reactivity in adults: An exploratory study.Physiological reports · 2026Article
- Unveiling the Origin of Regioselectivity in Iron(III)-Promoted Friedel-Crafts Synthesis of Cannabinoids: Theoretical Studies and Synthetic Applications.The Journal of organic chemistry · 2026Article
- An Exploration of Heart Rate Response and Blood Tetrahydrocannabinol (THC) Levels to Commercially Available Cannabis Edibles by Dose.Research square · 2026Article
- Rare but relevant: Cannabis use and myocardial infarction.Addiction (Abingdon, England) · 2025Review
- Exploring Cannabinoid Effects Using Zebrafish (International journal of molecular sciences · 2025Review
- Mechanisms of Cell Death Induced by Cannabidiol Against Tumor Cells: A Review of Preclinical Studies.Plants (Basel, Switzerland) · 2025Review
- Chromatographic and Spectroscopic Analyses of Cannabinoids: A Narrative Review Focused on Cannabis Herbs and Oily Products.Molecules (Basel, Switzerland) · 2025Review
- Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts.Pain and therapy · 2024Review
- Cannabis Use Variations and Myocardial Infarction: A Systematic Review.Journal of clinical medicine · 2024Review
- Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease.NPJ Parkinson's disease · 2024Article
- Inflammation and cancer: friend or foe?Frontiers in pharmacology · 2024Review
- Efficiency and safety of cannabinoid medical use: an analysis of discussions and observed trends on Instagram.Frontiers in public health · 2024Article
- Drug Interactions of Tetrahydrocannabinol and Cannabidiol in Cannabinoid Drugs.Deutsches Arzteblatt international · 2023Review
- The Polypharmacological Effects of Cannabidiol.Molecules (Basel, Switzerland) · 2023Review
- Should oncologists trust cannabinoids?Frontiers in pharmacology · 2023Review
- Cannabis and adverse cardiovascular events: A systematic review and meta-analysis of observational studies.Toxicology reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dronabinol, a natural cannabinoid, and its semi-synthetic derivative, nabilone, are marketed as medicines in several countries. The aim of our work was to systematically evaluate the frequency of adverse events related to dronabinol or nabilone treatment compared to placebo. Scientific databases were searched for placebo-controlled clinical studies of patients receiving either dronabinol or nabilone therapy with placebo control groups. This meta-analysis was reported following the PRISMA guidelines using the PICO format, and it was registered with the PROSPERO register. There were 16 trials included in the meta-analysis. In the nabilone studies, drowsiness was more than 7 times as frequent in patients treated with nabilone than in the placebo group (OR: 7.25; 95% CI: 1.64-31.95), and the risk of dizziness (OR: 21.14; 95% CI: 2.92-152.75) and dry mouth was also higher (OR: 17.23; 95% CI: 4.33-68.55). The frequency of headache was not different in the two groups. In case of dronabinol, the frequency of dry mouth (OR: 5.58; 95% CI: 3.19-9.78), dizziness (OR: 4.60 95% CI: 2.39-8.83) and headache (OR: 2.90; 95% CI: 1.07-7.85) was significantly higher in the dronabinol groups, whereas in case of nausea, drowsiness and fatigue there was no difference. The severity of adverse events was typically mild-to-moderate and transient. In a risk-benefit assessment, these adverse effects are acceptable compared to the achievable benefit. However, considering the diversity of the adverse effects, more studies are needed to provide a more accurate assessment on the side effect profiles of these two compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.